Corona Remedies IPO
UpcomingAlready have an account? Apply now
Corona Remedies IPO details
Schedule of Corona Remedies
| Issue open date | 08 Dec 2025 |
| Issue close date | 10 Dec 2025 |
| UPI mandate deadline | 10 Dec 2025 (5 PM) |
| Allotment finalization | 11 Dec 2025 |
| Refund initiation | 12 Dec 2025 |
| Share credit | 12 Dec 2025 |
| Listing date | 15 Dec 2025 |
| Mandate end date | 25 Dec 2025 |
| Lock-in end date for anchor investors (50%) | 10 Jan 2026 |
| Lock-in end date for anchor investors (remaining) | 11 Mar 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Corona Remedies
Corona Remedies, founded in 2004 and headquartered in Ahmedabad, Gujarat, is a pharmaceutical company engaged in the research, manufacturing, and marketing of healthcare products. The company offers a range of products across multiple therapeutic areas, including women’s healthcare, cardio-diabetes, pain management, urology, and more. With two manufacturing facilities located in Gujarat and Himachal Pradesh, Corona Remedies has established a significant presence in the Indian pharmaceutical market. The company’s growth strategy includes organic expansion and strategic acquisitions, aiming to enhance its product portfolio and market reach. Corona Remedies continues to focus on delivering quality healthcare solutions to meet the evolving needs of patients.
Financials of Corona Remedies
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 655.37 |
| Offer for sale – Proceeds go to the existing investors | 655.37 |
Strengths
- Consistent revenue growth with a CAGR of approximately 21% over the last three years.
- Diversified product portfolio across multiple therapeutic areas.
- Strong distribution network with a presence in urban and semi-urban areas.
- Leadership positions in specific therapeutic segments, such as women’s healthcare and pain management.
- EU-GMP and WHO-certified manufacturing facilities ensure high-quality production standards
Risks
- High working capital intensity with a gross operating cycle exceeding 150 days.
- Exposure to regulatory risks inherent in the pharmaceutical industry.
- Dependence on contract manufacturing for certain products.
- Ongoing capital expenditure projects with associated completion and cost risks.
- Presence in a competitive and price-controlled domestic pharmaceutical market.
Allotment Status for Corona Remedies
To check your IPO allotment status:
- Visit the Bigshare Services IPO Application Status page.
- Select the company name from the dropdown menu.
- Select and enter one of the following: PAN, Application Number, DP/Client ID, or Account Number/IFSC.
- Click Submit to view your allotment status.